required to treat patients who fail to respond to TKIs or experience unacceptable toxicity. New-generation targeted therapies such as immunotherapy and peptide receptor radionuclide therapy (PRRT) may be promising but require prospective randomised trials
Search Results
Anna Angelousi, Aimee R Hayes, Eleftherios Chatzellis, Gregory A Kaltsas, and Ashley B Grossman
Sara Pusceddu, Francesco Barretta, Annalisa Trama, Laura Botta, Massimo Milione, Roberto Buzzoni, Filippo De Braud, Vincenzo Mazzaferro, Ugo Pastorino, Ettore Seregni, Luigi Mariani, Gemma Gatta, Maria Di Bartolomeo, Daniela Femia, Natalie Prinzi, Jorgelina Coppa, Francesco Panzuto, Lorenzo Antonuzzo, Emilio Bajetta, Maria Pia Brizzi, Davide Campana, Laura Catena, Harry Comber, Fiona Dwane, Nicola Fazio, Antongiulio Faggiano, Dario Giuffrida, Kris Henau, Toni Ibrahim, Riccardo Marconcini, Sara Massironi, Maja Primic Žakelj, Francesca Spada, Salvatore Tafuto, Elizabeth Van Eycken, Jan Maaten Van der Zwan, Tina Žagar, Luca Giacomelli, Rosalba Miceli, and NEPscore Working Group
received by the patients during the course of the disease. However, since peptide receptor radionuclide therapy (PRRT) has been shown to prolong OS in midgut NET (interim analysis of the NETTER-1 trial) ( Strosberg et al . 2017 ), unlike other approved
Emanuel Christ, Kwadwo Antwi, Melpomeni Fani, and Damian Wild
localization of the tumor is the primary goal, the clinical challenge in metastasizing insulinomas is to define the extension of disease and – if possible – offer a targeted therapy (peptide receptor radionuclide therapy; PRRT). Contrary to benign insulinomas
J Crona, F Beuschlein, K Pacak, and B Skogseid
revised approach’ ( Grocott 2017 ). In addition, this study does not consider preoperative safety that is of concern in patients with catecholamine-secreting tumors. Oncological treatment Efficacy and safety of peptide receptor radionuclide therapy
Tobias Hofving, Yvonne Arvidsson, Bilal Almobarak, Linda Inge, Roswitha Pfragner, Marta Persson, Göran Stenman, Erik Kristiansson, Viktor Johanson, and Ola Nilsson
peptide receptor radionuclide therapy (PRRT) ( Kölby et al . 2005 , Bernhardt et al . 2007 , Forssell-Aronsson et al . 2013 , Dalmo et al . 2017 , Spetz et al . 2017 ). More recently, in 2009, three cell lines were established from a patient with
Susan Richter, Timothy J Garrett, Nicole Bechmann, Roderick J Clifton-Bligh, and Hans K Ghayee
have more slowly growing tumors, radiopharmaceutical agents, such as 131 I-metaiodobenzylguanidine targeting the norepinephrine transport system or peptide receptor radionuclide therapy (PRRT) taking advantage of somatostatin receptor type 2 expression
